Association between high-sensitivity cardiac troponin T levels and the predicted cardiovascular risk in middle-aged men without overt cardiovascular disease - 05/08/11
, Tomoyuki Kawada, MD a, Chikao Ibuki, MD b, Yoshihiko Seino, MD bRésumé |
Background |
A slight elevation of cardiac troponin T (TnT) levels in the circulating blood can be detected by the recently developed, high-sensitivity TnT (hsTnT) assay. However, it remains unclear whether a slight elevation of hsTnT is associated with an increased cardiovascular risk in subjects without overt cardiovascular disease (CVD).
Methods |
The serum hsTnT levels were measured in a work site-based population of 1,072 middle-aged males (mean age 44 years) without any history or presence of CVD. The lower detection limit of the hsTnT assay used in the present study was 0.002 ng/mL. The association of the hsTnT levels with cardiovascular risk factors and the predicted CVD risk, as determined by the Framingham CVD risk prediction score, were examined.
Results |
Detectable hsTnT levels were seen in 867 subjects (80.9%). The highest value of the hsTnT was 0.020 ng/mL. Among various cardiovascular risk factors, age, blood pressure, estimated glomerular filtration rate, current smoking, and left ventricular hypertrophy were independent determinants of hsTnT levels. The odds ratio for a high predicted CVD risk (10-year risk ≥20%) in the highest tertile of hsTnT (≥0.005 ng/mL) in comparison to the lowest tertile (≤0.002 ng/mL) was 3.98 (95% CI 1.72-9.24, P = .001) after adjusting for multiple potential confounders.
Conclusions |
The present study showed the hsTnT levels to be significantly associated with several cardiovascular risk factors and the predicted CVD risk in middle-aged men without overt CVD, thus suggesting the usefulness of measuring hsTnT to identify high-risk subjects in the primary prevention of CVD.
Le texte complet de cet article est disponible en PDF.Plan
Vol 159 - N° 6
P. 972-978 - juin 2010 Retour au numéro
Article précédent
- Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: Analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY) - Thrombolysis in Myocardial Infarction (TIMI) 28
- Matthew W. Sherwood, David A. Morrow, Benjamin M. Scirica, Songtao Jiang, Christoph Bode, Nader Rifai, Robert E. Gerszten, C. Michael Gibson, Christopher P. Cannon, Eugene Braunwald, Marc S. Sabatine
- Cockcroft-Gault is better than the Modification of Diet in Renal Disease study formula at predicting outcome after a myocardial infarction: Data from the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)
- Karolina Szummer, Pia Lundman, Stefan H. Jacobson, Johan Lindbäck, Ulf Stenestrand, Lars Wallentin, Tomas Jernberg, for SWEDEHEART
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?